The Journal of Diabetes Research and Technology
Jan 13, 2017 20:06:15 GMT -5
sportsrancho, harryx1, and 3 more like this
Post by careful2invest on Jan 13, 2017 20:06:15 GMT -5
The Need for Faster Insulin
Problem Solved?
Douglas B. Muchmore, MD
First Published January 1, 2017 review-article
PDF download for The Need for Faster Insulin Article Information
Full Access
Abstract
Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, overall glycemic control (A1C), and risk of hypoglycemia. An unmet need remains for a mealtime insulin that can faithfully reproduce the metabolic profile that ensues following meal ingestion in healthy persons. A number of “ultra-fast” insulin programs have been initiated, and Afrezza® (insulin human; Inhalation Powder, MannKind Corporation, Danbury, CT) stands as the first such product to be approved by the US FDA. Afrezza is unique as an “ultra-ultra” fast insulin, faster than any other entrant except IV insulin. The benefits and limitations of the Afrezza profile are discussed in this article. analysis.http://journals.sagepub.com/doi/abs/10.1177/1932296816677577 AND journals.sagepub.com/doi/pdf/10.1177/1932296816677577
Another positive read about AFREZZA!
We need more of this!
GLTA TRUE LONGS!
Problem Solved?
Douglas B. Muchmore, MD
First Published January 1, 2017 review-article
PDF download for The Need for Faster Insulin Article Information
Full Access
Abstract
Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, overall glycemic control (A1C), and risk of hypoglycemia. An unmet need remains for a mealtime insulin that can faithfully reproduce the metabolic profile that ensues following meal ingestion in healthy persons. A number of “ultra-fast” insulin programs have been initiated, and Afrezza® (insulin human; Inhalation Powder, MannKind Corporation, Danbury, CT) stands as the first such product to be approved by the US FDA. Afrezza is unique as an “ultra-ultra” fast insulin, faster than any other entrant except IV insulin. The benefits and limitations of the Afrezza profile are discussed in this article. analysis.http://journals.sagepub.com/doi/abs/10.1177/1932296816677577 AND journals.sagepub.com/doi/pdf/10.1177/1932296816677577
Another positive read about AFREZZA!
We need more of this!
GLTA TRUE LONGS!
